AU2019277679B2 - Methods for the treatment of bladder cancer - Google Patents

Methods for the treatment of bladder cancer Download PDF

Info

Publication number
AU2019277679B2
AU2019277679B2 AU2019277679A AU2019277679A AU2019277679B2 AU 2019277679 B2 AU2019277679 B2 AU 2019277679B2 AU 2019277679 A AU2019277679 A AU 2019277679A AU 2019277679 A AU2019277679 A AU 2019277679A AU 2019277679 B2 AU2019277679 B2 AU 2019277679B2
Authority
AU
Australia
Prior art keywords
compound
leu
pharmaceutically acceptable
vol
sting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019277679A
Other languages
English (en)
Other versions
AU2019277679A1 (en
Inventor
Xingfeng Bao
Hyeong-Wook Choi
Atsushi Endo
Frank Fang
Ming-Hong Hao
Kuan-Chun Huang
Dae-Shik Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2019277679A1 publication Critical patent/AU2019277679A1/en
Application granted granted Critical
Publication of AU2019277679B2 publication Critical patent/AU2019277679B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2019277679A 2018-06-01 2019-05-31 Methods for the treatment of bladder cancer Active AU2019277679B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862679495P 2018-06-01 2018-06-01
US62/679,495 2018-06-01
US201962826347P 2019-03-29 2019-03-29
US62/826,347 2019-03-29
PCT/US2019/034933 WO2019232392A1 (en) 2018-06-01 2019-05-31 Methods for the treatment of bladder cancer

Publications (2)

Publication Number Publication Date
AU2019277679A1 AU2019277679A1 (en) 2020-12-24
AU2019277679B2 true AU2019277679B2 (en) 2024-11-28

Family

ID=67138025

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019277679A Active AU2019277679B2 (en) 2018-06-01 2019-05-31 Methods for the treatment of bladder cancer

Country Status (11)

Country Link
US (1) US12251394B2 (https=)
EP (1) EP3801561B1 (https=)
JP (1) JP7335277B2 (https=)
KR (1) KR20210015937A (https=)
CN (1) CN112512531B (https=)
AU (1) AU2019277679B2 (https=)
BR (1) BR112020024605A2 (https=)
CA (1) CA3101623A1 (https=)
MX (1) MX2020012964A (https=)
SG (1) SG11202011434SA (https=)
WO (1) WO2019232392A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
JP2024533394A (ja) 2021-09-09 2024-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Stingアゴニストのバイオマーカー及びその使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
US20180344758A1 (en) 2014-12-17 2018-12-06 Lipogen Llc Method of Treating Cancer with cGAMP or cGAsMP
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック,インク. 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US20200055883A1 (en) * 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR102812783B1 (ko) 2017-08-31 2025-05-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル-マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド

Also Published As

Publication number Publication date
WO2019232392A1 (en) 2019-12-05
JP7335277B2 (ja) 2023-08-29
CN112512531A (zh) 2021-03-16
US12251394B2 (en) 2025-03-18
CA3101623A1 (en) 2019-12-05
US20210205348A1 (en) 2021-07-08
MX2020012964A (es) 2021-02-16
CN112512531B (zh) 2024-04-09
SG11202011434SA (en) 2020-12-30
EP3801561A1 (en) 2021-04-14
JP2021525758A (ja) 2021-09-27
BR112020024605A2 (pt) 2021-04-06
KR20210015937A (ko) 2021-02-10
EP3801561B1 (en) 2025-03-19
AU2019277679A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
US11339188B2 (en) Compounds for the treatment of cancer
EP3983384B1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
JP2022513392A (ja) 活性分子送達のための胆汁酸及びそれらの誘導体の抱合体
AU2019277679B2 (en) Methods for the treatment of bladder cancer
RU2795220C2 (ru) Способы лечения рака мочевого пузыря
CN112888677A (zh) 被取代的4-氨基-1H-咪唑并[4,5-c]喹啉化合物及其改进的制备方法
RU2790175C2 (ru) Циклические ди-нуклеотидные соединения для лечения рака
HK40016436B (en) Cyclic di-nucleotides compounds for the treatment of cancer
BR112019017084B1 (pt) Compostos dinucleotídeos cíclicos, composições farmacêuticas que compreendem os mesmos e uso dos ditos compostos para o tratamento de câncer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)